Morgan Stanley analyst Sean Laaman raised the firm’s price target on Exelixis (EXEL) to $48 from $47 and keeps an Overweight rating on the shares. The firm, which made model updates ahead of Q2 earnings due on Monday, July 28, and noted that its FY25 net product revenue estimate slightly increased to $2.105B, is watching for Zanza Phase 3 data in the second half.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis Receives Buy Rating Amid Positive Revenue Guidance and Anticipated Zanza Trial Data
- Exelixis Advances Cancer Treatment with New Phase 1 Study of XL309
- Exelixis price target raised to $56 from $55 at Truist
- Exelixis’ Phase 3 Trial: A New Hope for Renal Cell Carcinoma?
- Exelixis price target raised to $43 from $38 at UBS